The 17% decline in hospital-acquired conditions from 2010 to 2014 is the result of a decades long campaign and means lives saved, the avoidance of pain and suffering, and less costly care, said David Blumenthal, MD, MPP, president of The Commonwealth Fund.
The 17% decline in hospital-acquired conditions from 2010 to 2014 is the result of a decades long campaign and means lives saved, the avoidance of pain and suffering, and less costly care, said David Blumenthal, MD, MPP, president of The Commonwealth Fund.
Transcript (slightly modified)
Well the most important thing about the drop in hospital-acquired infections is that it means lives saved and people who haven’t been injured, families that haven’t been affected by the loss of loved ones or the burdens of caring for loved ones who are sick and suffering. It also has the benefit of saving money: avoided safety hazards usually result in less costly care.
Why is it happening now? I think there’s a combination of things. In large trends like this there is almost always multiple factors in play. We’ve had an almost 20-year campaign in the United States to improve safety of care. Perhaps that continuing campaign on behalf of thought leaders, leaders in the safety movement, public policy makers at the federal and state level, perhaps that’s finally penetrated into the work of our major institutions.
We also have had a series of new pay-for-performance programs that have highlighted the opportunity to reduce hospital-acquired, or healthcare-acquired, conditions—some of those are Medicare payments, some are private payments. So we know that payment has increasingly focused on pay-for-performance, including safety improvement.
And then the Affordable Care Act added some momentum when it was passed in 2010 and created penalties for higher-than-expected numbers of hospital-acquired conditions, and also provided technical support in the form of the Partnership for Patients, which is a national alliance of hospitals participating in safety improvement.
So I think there are a lot of things in play. There’s no question this is a very important set of statistics and I’m pretty confident they’re real, because they’re based to some extent on consistent measures developed by the Centers for Disease Control and Prevention, and reported nationally in a consistent way.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More